Regenxbio Inc (NAS:RGNX)
$ 10 0.08 (0.81%) Market Cap: 495.45 Mil Enterprise Value: 320.09 Mil PE Ratio: 0 PB Ratio: 1.64 GF Score: 65/100

Regenxbio Inc REGENXBIO RGX-314 Phase I/IIa Trial Update Transcript

Apr 22, 2020 / 12:30PM GMT
Release Date Price: $37.66 (+5.02%)
Operator

Good morning, and welcome to the REGENXBIO conference call to review additional positive long-term interim Phase I/IIa trial update for RGX-314 for the treatment of wet AMD. (Operator Instructions) As a reminder, this conference call is being recorded.

I would now like to turn the call over to Mr. Patrick Christmas, Senior Vice President and General Counsel for REGENXBIO. You may begin.

Patrick J. Christmas
REGENXBIO Inc. - Senior VP & Chief Legal Officer

Good morning, and thank you for joining us today. With us are Ken Mills, REGENXBIO's President and Chief Executive Officer; Dr. Steve Pakola, our Chief Medical Officer; and several esteemed retinal physicians and key opinion leaders: Dr. Allen Ho, Director of Retina Research at Wills Eye Hospital and Mid-Atlantic Retina; Dr. Robert Avery, Founder of California Retina Consultants and Research Foundation; and Dr. Peter Campochiaro, Director of the Retinal Cell and Molecular Laboratory at Johns Hopkins Wilmer Eye Institute.

Earlier this morning, REGENXBIO provided an update via press

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot